124 related articles for article (PubMed ID: 15233016)
1. [Determination proliferative activity of myeloma cells in histologic material].
Fabian P; Kren L; Nenutil R
Cesk Patol; 2004 Apr; 40(2):46-9. PubMed ID: 15233016
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
3. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens.
Costes V; Magen V; Legouffe E; Durand L; Baldet P; Rossi JF; Klein B; Brochier J
Hum Pathol; 1999 Dec; 30(12):1405-11. PubMed ID: 10667416
[TBL] [Abstract][Full Text] [Related]
4. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
6. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors.
Aref S; Goda T; El-Sherbiny M
Hematology; 2003 Aug; 8(4):221-8. PubMed ID: 12911939
[TBL] [Abstract][Full Text] [Related]
7. Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells.
Ak I; Aslan V; Vardareli E; Gülbaş Z
Ann Hematol; 2003 Feb; 82(2):88-92. PubMed ID: 12601486
[TBL] [Abstract][Full Text] [Related]
8. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
[TBL] [Abstract][Full Text] [Related]
9. Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence.
Cook JR; Hartke M; Pettay J; Tubbs RR
J Mol Diagn; 2006 Sep; 8(4):459-65. PubMed ID: 16931586
[TBL] [Abstract][Full Text] [Related]
10. [Syndecan-1 (CD138): an immunohistochemical marker of plasma cell tumors].
Fakan F; Boudová L; Hejda C
Cesk Patol; 2002 Jan; 38(1):33-6. PubMed ID: 11933459
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486.
Trendle MC; Leong T; Kyle RA; Katzmann JA; Oken MM; Kay NE; Van Ness BG; Greipp PR
Am J Hematol; 1999 Aug; 61(4):232-7. PubMed ID: 10440908
[TBL] [Abstract][Full Text] [Related]
12. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments.
Kumar S; Rajkumar SV; Greipp PR; Witzig TE
Am J Hematol; 2004 Sep; 77(1):7-11. PubMed ID: 15307099
[TBL] [Abstract][Full Text] [Related]
13. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders.
Witzig TE; Timm M; Larson D; Therneau T; Greipp PR
Br J Haematol; 1999 Jan; 104(1):131-7. PubMed ID: 10027725
[TBL] [Abstract][Full Text] [Related]
14. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression.
Rawstron A; Barrans S; Blythe D; Davies F; English A; Pratt G; Child A; Morgan G; Jack A
Br J Haematol; 1999 Jan; 104(1):138-43. PubMed ID: 10027726
[TBL] [Abstract][Full Text] [Related]
15. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms.
O'Connell FP; Pinkus JL; Pinkus GS
Am J Clin Pathol; 2004 Feb; 121(2):254-63. PubMed ID: 14983940
[TBL] [Abstract][Full Text] [Related]
16. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
[TBL] [Abstract][Full Text] [Related]
17. [Proliferative activity of myeloma cells determined by Ki-67 antibody: biological and clinical significance].
Marković O; Marisavljević D; Cemerikić V; Vidović A; Bakrac M; Perunicić M; Suvajdzić N; Colović M
Vojnosanit Pregl; 2005 Jan; 62(1):33-8. PubMed ID: 15715347
[TBL] [Abstract][Full Text] [Related]
18. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death.
Steensma DP; Gertz MA; Greipp PR; Kyle RA; Lacy MQ; Lust JA; Offord JR; Plevak MF; Therneau TM; Witzig TE
Blood; 2001 Apr; 97(8):2522-3. PubMed ID: 11290618
[TBL] [Abstract][Full Text] [Related]
19. BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.
Requirand G; Robert N; Boireau S; Vincent L; Seckinger A; Bouhya S; Ceballos P; Cartron G; Hose D; Klein B; Moreaux J
Cytometry B Clin Cytom; 2019 May; 96(3):209-214. PubMed ID: 30417559
[TBL] [Abstract][Full Text] [Related]
20. Seemingly insignificant, but crucial morphological leads in the diagnosis of non-secretory multiple myeloma in an adolescent.
Mishra J; Chopra A; Gogia A; Kumar R
Indian J Pathol Microbiol; 2012; 55(1):130-2. PubMed ID: 22499328
[No Abstract] [Full Text] [Related]
[Next] [New Search]
